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Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile
Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and
Crohn's Disease
Gerd Horneff, MD1, Marieke M. B. Seyger, MD, PhD2, Dilek Arikan, MD3, Jasmina Kalabic, MD4, Jaclyn K. Anderson, DO, MS3,
Andreas Lazar, MD4, David A. Williams, MD, MPH3, Chen Wang, PhD3,*, Rita Tarzynski-Potempa, MD3, and
Jeffrey S. Hyams, MD5
Objective To evaluate the safety of adalimumab in pediatric patients who participated in clinical trials of juvenile
idiopathic arthritis (polyarticular juvenile idiopathic arthritis and pediatric enthesitis-related arthritis), psoriasis, and
Crohn’s disease.
Study design This analysis included data from 7 global, randomized, and open-label AbbVie-sponsored clinical
trials of adalimumab and their open-label extensions conducted between September 2002 and December 31, 2015
(cutoff date for ongoing studies). Patients who received ≥1 dose of adalimumab subcutaneously were included.
Adverse events that occurred after the first dose of adalimumab and up to 70 days (5 half-lives) after the last dose
were reported and events per 100 patient-years were calculated.
Results The analysis included 577 pediatric patients, representing 1440.7 patient-years of adalimumab expo-
sure. Across indications, the most commonly reported adverse events (events/100 patient-years) were upper re-
spiratory tract infections (24.3), nasopharyngitis (17.3), and headache (19.9). Serious infections (4.0 events/100
patient-years) were the most frequent serious adverse events across indications; the most commonly reported was
pneumonia (0.6 events/100 patient-years). Serious infection rates were 2.7, 0.8, and 6.6 events/100 patient-years
in patients with juvenile idiopathic arthritis, psoriasis, and Crohn’s disease, respectively. No events of malignan-
cies were reported. One death (accidental fall) occurred in a patient with psoriasis.
Conclusions The safety profile of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis,
enthesitis-related arthritis, psoriasis, and Crohn’s disease was generally similar across indications; no new safety
signals were identified in the treatment of pediatric patients with adalimumab. (J Pediatr 2018;201:166-75).
Trial registration Clinicaltrials.gov: NCT00048542, NCT00775437, NCT00690573, NCT01166282, NCT01251614,
NCT00409682, and NCT00686374.
A dalimumab is an anti−tumor necrosis factor (TNF) monoclonal anti-body that has demonstrated safety and efficacy in multiple pediatric con-ditions, including polyarticular juvenile idiopathic arthritis (pJIA),1-3
enthesitis-related arthritis (ERA),4 pediatric psoriasis,5 and pediatric Crohn’s disease
(CD).6,7 Currently, the approved pediatric indications for adalimumab in the US
and European Union include moderately to severely active pJIA in patients ≥2 years
of age and moderate to severely active pediatric CD in patients ≥6 years of age
with previous inadequate response to conventional therapy.8 Additional ap-
proved indications for adalimumab in the European Union include the treat-
ment of active ERA in patients ≥6 years of age with an inadequate response to or
intolerance of conventional therapy and the treatment of severe chronic plaque
AE Adverse event
CD Crohn’s disease
CHF Congestive heart failure
ERA Enthesitis-related arthritis
JIA Juvenile idiopathic arthritis
NCT National Clinical Trial
pJIA Polyarticular juvenile idiopathic arthritis
PY Patient-year
SAE Serious adverse event
TB Tuberculosis
TNF Tumor necrosis factor
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psoriasis in children and adolescents ≥4 years of age who have
had an inadequate response to or are inappropriate candi-
dates for topical therapy and phototherapies.9
The safety of adalimumab, especially long term, is an im-
portant consideration in the pediatric population, as each in-
dication represents a distinct chronic condition. An analysis
of adverse event (AE) data across multiple indications from
23 458 patients (mostly adults), some of whom had clinical
trial exposure to adalimumab for almost 12 years, found that
although rates of specific AEs varied by disease, the overall safety
profile was consistent with that of anti-TNF agents as a class10;
no new safety signals were identified. Although interim data
from ongoing pediatric registries for pJIA, CD, and psoriasis
are emerging,11-15 pediatric safety data for adalimumab remain
limited relative to adult safety data. Therefore, examining safety
data within and across multiple therapeutic areas specifically
in pediatric populations from controlled clinical trials may
provide additional, valuable safety information. Safety events
of special interest in the pediatric population include infec-
tions (particularly serious infections and opportunistic infec-
tions), malignancies, and hypersensitivity.
This analysis was conducted to evaluate the totality of safety
findings from pediatric studies of adalimumab, including long-
term analyses (>52 weeks), by assessing AEs in pediatric pa-
tients who participated in clinical trials of juvenile idiopathic
arthritis (JIA; pJIA and ERA), psoriasis, and CD. Data from
these studies reflect the longest clinical study exposure to
adalimumab published to date for each indication.1-7
Methods
Clinical Trials
Safety findings from 7 AbbVie-sponsored, global clinical trials
of adalimumab (subcutaneous injection; 40 mg/0.8-mL or
20 mg/0.4-mL formulation) in pediatric patients were in-
cluded in this analysis: 4 studies of rheumatic disease, includ-
ing pJIA (National Clinical Trial [NCT] no. 00048542,
NCT00775437, NCT00690573) and ERA (NCT01166282); 1
study of pediatric psoriasis (NCT01251614); and 1 study of
pediatric CD (NCT00409682), including its ongoing open-
label extension (NCT00686374).Methods and results from these
studies are published (briefly summarized in Table I)1-7 All study
protocols were approved by an institutional review board or
independent ethics committee, and written informed consent
was obtained from patients, parents, or legal guardians.
Safety Assessments
This analysis included all AEs that occurred after the first dose
of adalimumab and up to 70 days (5 half-lives) after the last
dose (ie, all treatment-emergent AEs); data are presented
through December 31, 2015. An analysis of infections by con-
comitant corticosteroid use also was conducted.AEs were coded
using the Medical Dictionary for Regulatory Activities, version
18.1. AEs of special interest included infections and serious in-
fections, opportunistic infections (due to bacterial, mycobac-
terial, invasive fungal, viral, parasitic, or other opportunistic
pathogens),16 malignancies, and hypersensitivity reactions.
Serious adverse events (SAEs) were defined as events that were
fatal or immediately life-threatening; required inpatient or pro-
longed hospitalization; resulted in persistent or significant
disability/incapacity, congenital anomaly, or spontaneous or
elective abortion; or required medical or surgical interven-
tion to prevent a serious outcome.
Growth/height analyses were performed in 2 patient popu-
lations. In the pJIA study,3 patients were pooled and divided
into 2 groups based on their baseline height percentile (<33
or >33) on the Centers for Disease Control and Prevention
growth chart.17 Height and body mass index and improve-
ment of pJIA signs and symptoms were evaluated. In the CD
study,6 height velocity z scores based on bone age were
calculated using reference standard height velocity tables ac-
cording to the following equation: (observed height velocity
– median height velocity for age and sex)/SD of the median.
Patients with height velocity z score ≤–1.0 were considered to
have growth delay at baseline.18 Change from baseline in height
velocity z score was evaluated in patients with and without
growth delay at baseline.
Statistical Analyses
Patients who received ≥1 dose of adalimumab were included
in this pediatric safety analysis. AEs are presented as the number
and proportion of patients experiencing each event and as the
number of events and rate of events per 100 patient-years (PY).
A Kaplan–Meier analysis was used to evaluate the time to first
serious infectious event for each indication. Height and growth
analyses were reported as observed data. For the CD growth
analyses, the Wilcoxon rank sum test was used to compare
change from baseline (2-sided, 5% level of significance).
Results
Baseline Characteristics and Adalimumab
Exposure
This analysis included 577 pediatric patients (Figure 1; avail-
able at www.jpeds.com), representing 1440.7 PY of exposure
(Table II). A total of 274 patients with JIA (806.9 PY), includ-
ing 228 patients representing 662.3 PY in 3 pJIA studies and
46 patients representing 144.5 PY in the pediatric ERA study,
111 patients with pediatric psoriasis (121.5 PY), and 192 pa-
tients with pediatric CD (512.3 PY), were included in the analy-
sis. Baseline characteristics for these pediatric populations are
summarized in Table II.
AEs
Most patients in each therapeutic area reported at least 1 AE
(Table III). The most common types of AEs (including both
serious and nonserious events) were infections and injection-
site reactions, including injection-site pain. Overall, infec-
tions occurred in 82% of patients with JIA (150.7 events/100
PY), 74% of patients with psoriasis (168.7 events/100 PY), and
76% of patients with CD (132.0 events/100 PY). Across all pe-
diatric indications, the most commonly reported individual
AEs were upper respiratory tract infections (27%; 24.3 events/
100 PY), nasopharyngitis (24%; 17.3 events/100 PY), and
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Table I. Overview of pediatric studies included in the current safety analysis
Authors; Clinicaltrials.gov
identifiers Year Disease
Age
range, y No. Study design (sites); dosing regimen
Lovell et al3; NCT00048542 2008 pJIA 4-17 171 Randomized, double-blind, placebo-controlled, stratified, parallel-
group, multicenter study (Belgium, Czech Republic, France,
Germany, Italy, Slovakia, Spain, and the US) conducted between
September 2002 and January 2005
16-wk, open-label lead-in, followed by 32-wk, double-blind
treatment: 24 mg/m2 BSA adalimumab up to a maximum of
40 mg EOW
Open-label extension phase: dose initially based on BSA, followed by
a fixed dose based on body weight (20 mg if <30 kg; 40 mg if
≥30 kg)
Kingsbury et al1; NCT00775437 2014 pJIA 2 to <4* 32 Open-label, single-arm, multicenter study (Czech Republic, France,
Germany, and the US) conducted between March 2009 and March
2013
24 mg/m2 BSA (up to maximum 20 mg) adalimumab EOW for
≥24 wk
Imagawa et al2; NCT00690573 2012 pJIA 4-17 25 Open-label, single-arm, multicenter study (Japan) conducted
between May 2008 and August 2010
20 mg adalimumab EOW if <30 kg or 40 mg adalimumab EOW if
≥30 kg up to wk 16 (dose redetermined by body weight at wk 16
and every 12 wk after wk 24 through wk 60)
Burgos-Vargas et al4;
NCT01166282
2015 Pediatric ERA ≥6 to <18 46 12-wk, double-blind, placebo-controlled, multicenter study with an
early escape option, followed by an open-label adalimumab EOW
treatment period with a maximum duration of 192 wk (maximum
total duration, 204 wk; Canada, France, Germany, Italy, Mexico,
Poland, Spain, Sweden, and Switzerland) conducted between
September 2010 and December 2015
24 mg/m2 BSA (up to 40 mg) adalimumab EOW
Papp et al5; NCT01251614 2017 Chronic pediatric
plaque psoriasis
≥4 to <18 111† Randomized, double-blind, multicenter study (Belgium, Canada,
Chile, Czech Republic, Germany, Hungary, Italy, Mexico,
Netherlands, Poland, Spain, Switzerland, and Turkey) conducted
between December 2010 and February 2015
Period A: initial treatment, adalimumab 0.8 mg/kg, 0.4 mg/kg, or
methotrexate for 16 wk; early escape to period D option available
up to wk 8; at wk 16, responders enter period B and
nonresponders enter period D
Period B: withdrawal, lasting no longer than 36 wk; at point of loss of
disease control, patients enter period C; patients who do not lose
control of their disease enter period D and remain off treatment
Period C: retreatment, double-blind treatment with adalimumab for
16 wk (patients receive same randomized adalimumab dose as in
period A, patients randomized to methotrexate receive 0.8 mg/kg
adalimumab)
Period D: long-term follow-up treatment with adalimumab for up to
52 wk
Hyams et al6; NCT00409682;
IMAgINE I
2012 Moderate-to-severe
pediatric CD
6-17 192 Randomized, double-blind multicenter study (Belgium, Canada,
France, Netherlands, Poland, United Kingdom, and US) conducted
between April 2007 and May 2010
Weight-based, open-label induction regimen of adalimumab at wk 0
and 2 (160 and 80 mg, respectively, if ≥40 kg; 80 and 40 mg if
<40 kg) with subsequent randomization to 1 of 2 weight-based
treatment arms of maintenance adalimumab:
High-dose group: 40 mg EOW if ≥40 kg or 20 mg EOW if <40 kg at
wk 4
Low-dose group: 20 mg EOW if ≥40 kg or 10 mg EOW if <40 kg at
wk 4
At wk 26, maintenance dosing adjusted for patients whose body
weight increased from <40 to ≥40 kg
Faubion et al7; NCT00686374;
IMAgINE II extension study
2017 Moderate- to-severe
pediatric CD
7-18 100 Patients who successfully completed IMAgINE I and responded to
treatment received weight-based open-label adalimumab
maintenance therapy for up to 408 wk; study started May 2008
Patients enrolled from double-blind therapy in IMAgINE I; patients
≥40 kg received 40 mg adalimumab EOW and patients <40 kg
received 20 mg adalimumab EOW
Patients who enrolled from open-label therapy in IMAgINE I
continued to receive 40 or 20 mg EW
BSA, body surface area; EOW, every other week; EW, every week.
*≥4 y and weight <15 kg.
†114 patients enrolled; however, only 111 patients received a dose of adalimumab and were included in the pediatric psoriasis data analysis.
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headache (24%; 19.9 events/100 PY; Table IV; available at
www.jpeds.com). Within each indication, the most com-
monly reported individual AEs were injection-site pain (22%
of patients; 74.7 events/100 PY) in patients with JIA; head-
ache (30%; 46.9 events/100 PY) in patients with psoriasis; and
worsening of CD (55%; 36.7 events/100 PY) in patients with
CD (Table IV).
Rates of AEs of special interest were generally low (Table III).
Allergic reactions occurred in 15% of patients with JIA (7.7
events/100 PY), 6% of patients with psoriasis (7.4 events/100
PY), and 10% of patients with CD (4.9 events/100 PY). Oral
candidiasis and tuberculosis (TB; including active and latent)
each occurred in 1% of patients across all indications (0.6
events/100 PY and 0.4 events/100 PY, respectively); notably,
only 1 patient had active TB (<0.1 events/100 PY). This case
of disseminated TB occurred in a male patient with ERA from
Mexico with a history of latent TB at baseline; the patient en-
rolled on TB prophylaxis (confirmed compliance with 7months
of isoniazid). After >2.5 years on study, at age 19 years, symp-
tomatic miliary TB was diagnosed. Adalimumab was discon-
tinued permanently; after successful treatment for TB, he was
doing well as of last follow-up, approximately 1 year later. The
investigator and the sponsor considered the event probably
related to the study drug.
Other opportunistic infections occurred in 1% of patients
across all indications (0.3 events/100 PY), and herpes zoster
occurred in 3% of patients across all indications (1.5 events/
100 PY). Of the 19 patients with 21 herpes zoster events, 3 pa-
tients had serious events; all 3 patients recovered after treatment
with acyclovir and did not receive further prophylaxis.
Overall, injection-site reactions were reported in 37% of pa-
tients with JIA (104.6 events/100 PY), 10% of patients with
psoriasis (14.0 events/100 PY), and 22% of patients with CD
(20.3 events/100 PY; Table III); most injection-site reaction
events (>95%) were considered by the investigator to be mild
or moderate. One patient with CD discontinued study drug
due to an injection-site reaction while receiving open-label
adalimumab.
Worsening or new onset of psoriasis occurred in 4% of pa-
tients overall (1.7 events/100 PY); rates in JIA, pediatric CD,
and pediatric psoriasis were 0.7, 1.4, and 9.1 events/100 PY,
respectively. Uveitis occurred in 1% of patients overall (0.6
events/100 PY); there were no events in pediatric patients with
psoriasis, and rates in JIA and pediatric CD were 0.7 and 0.4
events/100 PY, respectively. There were no malignancies re-
ported. In addition, there were no cases of demyelinating dis-
orders, reactivation of hepatitis B, or Stevens–Johnson
syndrome.
Serious Adverse Events
SAEs occurred in 29% of all patients (19.6 events/100 PY). Rates
of SAEs in pediatric patients with JIA, psoriasis, and CD were
13.5, 7.4, and 32.2 events/100 PY, respectively (Table V). Serious
infections were the most frequent SAEs across indications (8%
of all patients; 4.0 events/100 PY). The rates of serious infec-
tions in patients with JIA, psoriasis, and CD were 2.7, 0.8, and
6.6 events/100 PY, respectively, including typical CD-related
complications such as abdominal and anal abscess in pa-
tients with CD. CD-related complications (2 events of anal
abscess and 1 event each of pelvic abscess, peritonitis, abdomi-
nal abscess, and perirectal abscess) accounted for 6 of the 20
events of serious infection that occurred after 500 days of
therapy in patients with CD. Pneumonia was the most com-
monly reported serious infection (1% of all patients; 0.6 events/
100 PY). The risk of first serious infection remained stable for
the duration of the study for all indications (Figure 2).
Other common SAEs included exacerbation of the under-
lying disease (Table IV). For example, worsening of CD ac-
counted for nearly one-half of the SAEs among patients with
CD (15.4 events/100 PY). SAEs of diffuse vasculitis and
Table II. Demographics, concomitant therapy, and adalimumab exposure
Baseline characteristics JIA (n = 274) Pediatric psoriasis (n = 111) Pediatric CD (n = 192) Total (n = 577)
Mean age, y 10.7 13.0 13.6 12.1
Mean disease duration,* y 3.2 5.0 3.0 3.5
Female, n (%) 198 (72.3) 62 (55.9) 84 (43.8) 344 (59.6)
Received previous anti-TNF,† n (%) 0 11 (9.9) 84 (43.8) 95 (16.5)
Concomitant therapy‡
Immunomodulating agents,§ n (%) 154 (56.2) 1 (0.9) 126 (65.6) 281 (48.7)
Systemic corticosteroids,¶ n (%) 117 (42.7) 4 (3.6) 104 (54.2) 225 (39.0)
Adalimumab exposure
PY 806.9 121.5 512.3 1440.7
Median duration of exposure, PY 2.9 1.1 1.2 1.6
Maximum duration of exposure, PY 6.9 1.7 7.7 7.7
>2-y exposure, n (%) 172 (62.8) 0 82 (42.7) 254 (44.0)
>5-y exposure, n (%) 63 (23.0) 0 51 (26.6) 114 (19.8)
*JIA, n = 273; total, n = 576.
†Previous anti-TNF use was an exclusion criterion in the JIA studies; in pediatric psoriasis, previous anti-TNF use was excluded with the exception of etanercept (but not allowed within 4 weeks
of baseline); in pediatric CD, previous infliximab use was allowed (but not within 8 wk of baseline).
‡At baseline and/or during the study.
§Including methotrexate, sulfasalazine, and hydroxychloroquine for JIA; mesalazine (for colitis that manifested >70 days after last dose of adalimumab) for psoriasis; and azathioprine, 6-mercaptopurine,
or methotrexate for CD.
¶For JIA, changes in concomitant corticosteroid use were not permitted during the blinded portions of any study but changes were possible in open-label extension studies; for psoriasis, corti-
costeroid use was not permitted during the study but 4 patients received short courses of therapy for medical conditions other than psoriasis (bronchial obstructive syndrome, bronchospasm,
upper respiratory tract infection, and preplanned cosmetic surgery); for CD, corticosteroids could be discontinued in IMAgINE I and II studies.
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Table III. Overview of AEs in adalimumab pediatric clinical trials*
Adverse event (AE)
JIA (n = 274) Pediatric psoriasis (n = 111) Pediatric CD (n = 192) Total (n = 577)
No. (%)
Events
(events/100 PY) No. (%)
Events
(events/100 PY) No. (%)
Events
(events/100 PY) No. (%)
Events
(events/100 PY)
Exposure, PY NA 806.9 NA 121.5 NA 512.3 NA 1440.7
Any AEs 267 (97.4) 4239 (525.3) 100 (90.1) 630 (518.5) 189 (98.4) 2902 (566.5) 556 (96.4) 7771 (539.4)
AE related to study drug† 200 (73.0) 1536 (190.4) 48 (43.2) 176 (144.9) 115 (59.9) 621 (121.2) 363 (62.9) 2333 (161.9)
Serious AEs 67 (24.5) 109 (13.5) 8 (7.2) 9 (7.4) 92 (47.9) 165 (32.2) 167 (28.9) 283 (19.6)
Severe AE 45 (16.4) 67 (8.3) 17 (15.3) 24 (19.8) 67 (34.9) 114 (22.3) 129 (22.4) 205 (14.2)
AE leading to discontinuation 24 (8.8) 31 (3.8) 3 (2.7) 3 (2.5) 61 (31.8) 77 (15.0) 88 (15.3) 111 (7.7)
AE leading to death 0 0 1 (0.9) 1 (0.8) 0 0 1 (0.2) 1 (<0.1)
Infection 224 (81.8) 1216 (150.7) 82 (73.9) 205 (168.7) 145 (75.5) 676 (132.0) 451 (78.2) 2097 (145.6)
Serious infection 21 (7.7) 22 (2.7) 1 (0.9) 1 (0.8) 25 (13.0) 34 (6.6) 47 (8.1) 57 (4.0)
Herpes zoster 8 (2.9) 9 (1.1) 3 (2.7) 3 (2.5) 8 (4.2) 9 (1.8) 19 (3.3) 21 (1.5)
Oral candidiasis 2 (0.7) 2 (0.2) 0 0 3 (1.6) 6 (1.2) 5 (0.9) 8 (0.6)
Any parasitic infection 3 (1.1) 5 (0.6) 0 0 1 (0.5) 1 (0.2) 4 (0.7) 6 (0.4)
TB 3 (1.1) 3 (0.4) 2 (1.8) 2 (1.6) 1 (0.5) 1 (0.2) 6 (1.0) 6 (0.4)
Active 1 (0.4) 1 (0.1) 0 0 0 0 1 (0.2) 1 (<0.1)
Latent 2 (0.7) 2 (0.2) 2 (1.8) 2 (1.6) 1 (0.5) 1 (0.2) 5 (0.9) 5 (0.3)
Opportunistic infection (excluding TB and oral candidiasis)‡ 0 0 0 0 4 (2.1) 4 (0.8) 4 (0.7) 4 (0.3)
Injection-site reaction§ 101 (36.9) 844 (104.6) 11 (9.9) 17 (14.0) 42 (21.9) 104 (20.3) 154 (26.7) 965 (67.0)
Allergic reaction¶ 41 (15.0) 62 (7.7) 7 (6.3) 9 (7.4) 19 (9.9) 25 (4.9) 67 (11.6) 96 (6.7)
Hematologic disorders** 10 (3.6) 16 (2.0) 2 (1.8) 3 (2.5) 27 (14.1) 36 (7.0) 39 (6.8) 55 (3.8)
Worsening/new onset of psoriasis 5 (1.8) 6 (0.7) 10 (9.0) 11 (9.1) 6 (3.1) 7 (1.4) 21 (3.6) 24 (1.7)
Intestinal stricture 0 0 0 0 7 (3.6) 8 (1.6) 7 (1.2) 8 (0.6)
Intestinal perforation 0 0 0 0 2 (1.0) 2 (0.4) 2 (0.3) 2 (0.1)
Uveitis 4 (1.5) 6 (0.7) 0 0 1 (0.5) 2 (0.4) 5 (0.9) 8 (0.6)
Liver event†† 5 (1.8) 5 (0.6) 0 0 1 (0.5) 1 (0.2) 6 (1.0) 6 (0.4)
Vasculitis 1 (0.4) 2 (0.2) 0 0 0 0 1 (0.2) 2 (0.1)
Noncutaneous 1 (0.4) 2 (0.2) 0 0 0 0 1 (0.2) 2 (0.1)
Cutaneous 0 0 0 0 0 0 0 0
CHF 1 (0.4) 1 (0.1) 0 0 0 0 1 (0.2) 1 (<0.1)
Lupus-like reaction and systemic lupus erythematosus 0 0 0 0 1 (0.5) 1 (0.2) 1 (0.2) 1 (<0.1)
Pancreatitis 0 0 0 0 1 (0.5) 1 (0.2) 1 (0.2) 1 (<0.1)
Malignancy 0 0 0 0 0 0 0 0
NA, not applicable.
*Serious and nonserious events are included. There were no cases of demyelinating disorders, reactivation of hepatitis B, pulmonary embolism, Stevens–Johnson syndrome, erythema multiforme, legionella, diverticulitis, progressive multiforme leukoencepha-
lopathy, sarcoidosis, autoimmune hepatitis, cerebrovascular accident, interstitial lung disease, or reversible posterior leukoencephalopathy. The numbers of AEs (most notably allergic reactions) in the current analysis of pediatric CD differ from the report by
Faubion et al7 because of methodology. Safety outcomes in Faubion et al were derived from adjudication of standardized Medical Dictionary for Regulatory Activities version 13.1 search results using a January 31, 2015 cut-off date; here, data are based on
company-defined search criteria of Medical Dictionary for Regulatory Activities version 18.1 using a December 31, 2015 cut-off date.
†As assessed by the investigator.
‡Includes 1 event each of Aeromonas infection, fungal esophagitis, histoplasmosis disseminated, and esophageal candidiasis.
§Including application-site rash, reaction, and swelling; injection-site bruising, discoloration, discomfort, erythema, hematoma, irritation, nodule, pain, paresthesia, pruritus, rash, reaction, swelling, urticaria, and warmth.
¶Reported events included eye pruritus, eyelid edema, injection-site urticaria, drug hypersensitivity, hypersensitivity, asthma, bronchospasm, wheezing, pruritus generalized, rash, rash generalized, and urticaria.
**Including anemia, cytopenia, leukopenia, lymphopenia, microcytic and macrocytic anemia, and neutropenia.
††Including hepatitis, hepatocellular injury, hepatotoxicity, and liver disorder.
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Table V. SAEs occurring in ≥1% of patients in any indication across adalimumab pediatric clinical trials
SAEs
JIA (n = 274) Pediatric psoriasis (n = 111) Pediatric CD (n = 192) Total (n = 577)
No. (%)
Events
(events/100 PY) No. (%)
Events
(events/100 PY) No. (%)
Events
(events/100 PY) No. (%)
Events
(events/100 PY)
Exposure, PY NA 806.9 NA 121.5 NA 512.3 NA 1440.7
Any SAE 67 (24.5) 109 (13.5) 8 (7.2) 9 (7.4) 92 (47.9) 165 (32.2) 167 (28.9) 283 (19.6)
SAEs occurring in ≥1% of patients in any group
Worsening of CD* 0 0 0 0 61 (31.8) 79 (15.4) 61 (10.6) 79 (5.5)
Worsening of JIA* 16 (5.8) 23 (2.9) 0 0 0 0 16 (2.8) 23 (1.6)
Anemia 0 0 0 0 4 (2.1) 6 (1.2) 4 (0.7) 6 (0.4)
Pyrexia 2 (0.7) 2 (0.2) 0 0 2 (1.0) 2 (0.4) 4 (0.7) 4 (0.3)
Arthritis 3 (1.1) 3 (0.4) 0 0 0 0 3 (0.5) 3 (0.2)
Adenoidal hypertrophy 3 (1.1) 3 (0.4) 0 0 0 0 3 (0.5) 3 (0.2)
Tonsillar hypertrophy 3 (1.1) 3 (0.4) 0 0 0 0 3 (0.5) 3 (0.2)
Gastritis 0 0 0 0 2 (1.0) 2 (0.4) 2 (0.3) 2 (0.1)
Small intestinal obstruction 0 0 0 0 2 (1.0) 2 (0.4) 2 (0.3) 2 (0.1)
Tachycardia 0 0 0 0 2 (1.0) 2 (0.4) 2 (0.3) 2 (0.1)
Serious infections 21 (7.7) 22 (2.7) 1 (0.9) 1 (0.8) 25 (13.0) 34 (6.6) 47 (8.1) 57 (4.0)
Serious infections occurring in ≥1% of patients in any group
Pneumonia 4 (1.5) 4 (0.5) 0 0 2 (1.0) 4 (0.8) 6 (1.0) 8 (0.6)
Appendicitis 4 (1.5) 4 (0.5) 0 0 0 0 4 (0.7) 4 (0.3)
Abdominal abscess 0 0 0 0 3 (1.6) 4 (0.8) 3 (0.5) 4 (0.3)
Herpes zoster 3 (1.1) 3 (0.4) 0 0 0 0 3 (0.5) 3 (0.2)
Anal abscess 0 0 0 0 3 (1.6) 3 (0.6) 3 (0.5) 3 (0.2)
Gastroenteritis 0 0 0 0 2 (1.0) 2 (0.4) 2 (0.3) 2 (0.1)
Subcutaneous abscess 0 0 0 0 2 (1.0) 2 (0.4) 2 (0.3) 2 (0.1)
*Worsening refers to worsening of the underlying disease.
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congestive heart failure (CHF) occurred in a 16-year-old female
patient with ERA. The event of CHF occurred in conjunc-
tion with pneumonia on day 441 during a complex
hospitalization subsequent to the diagnosis of diffuse vascu-
litis on day 433.Adalimumab was discontinued because of these
events. The investigator considered the event of diffuse vas-
culitis probably related and the events of CHF and pneumo-
nia probably not related to study drug. One death, due to an
accidental fall, occurred in an adolescent patient with psoriasis.
AEs by Concomitant Corticosteroid Use
Greater incidences and rates of infections were observed in pa-
tients who received concomitant systemic corticosteroids vs
those who did not in the overall study population (84% [158.5
events/100 PY] vs 75% [134.4 events/100 PY], respectively) as
well as among patients with JIA (87% [169.6 events/100 PY]
vs 78% [134.7 events/100 PY]), psoriasis (100% [196.4 events/
100 PY] vs 73% [167.2 events/100 PY), and CD (79% [143.6
events/100 PY] vs 72% [116.4 events/100 PY]); of note, only
4 patients with psoriasis received systemic corticosteroids
(Table VI and Table VII; available at www.jpeds.com). Simi-
larly, incidences and rates of serious infections were greater
among patients who received concomitant systemic cortico-
steroids vs those who did not, with the exception of patients
with psoriasis, in whom serious infections were rare (1 event
in a patient not receiving concomitant corticosteroids).
Growth
In patients with pJIA, long-term treatment with adalimumab
was associated with improvement and maintenance of growth
among patients in the ≤33rd percentile group for baseline height
(n = 73) and improved pJIA signs and symptoms regardless
of baseline growth status.19 In the CD study, adalimumab sig-
nificantly normalized the growth rate by week 26 (median
height velocity z score, −0.34) and week 52 (0.21; both P < .001)
in patients with baseline growth impairment (n = 73).18 Linear
growth remained stable over time in patients without base-
line growth impairment (n = 27).
Discussion
The current analysis adds to a more complete understanding
of the established safety profile of adalimumab and demon-
strated that in pediatric patients with pJIA, ERA, psoriasis, and
CD, the overall safety profile was comparable and consistent
with that in adults. This analysis included patients withmedium
to long-term exposure to adalimumab (median duration of ex-
posure 1.1-2.9 years across indications) and collectively rep-
resents the largest number of pediatric patients exposed to
adalimumab for the longest length of time to date.
The most commonly reported individual AEs were upper
respiratory tract infections, nasopharyngitis, and headache,
which are not unusual in the pediatric population. The inci-
dence and types of AEs and SAEs varied by disease, with mark-
edly greater rates of SAEs (48%) and serious infections (13%)
reported among patients with pediatric CD; however, some of
these AEs may be related to a greater infection risk with CD
itself20-22 or worsening of CD. Similar to our findings, the col-
lective safety data from an analysis of adults receiving
adalimumab showed a greater rate of serious infections among
patients with CD relative to other indications10; of note, some
of the serious infections in our current analysis are common
complications of CD (eg, abscesses).
There is a known risk of infection associated with anti-
TNF therapy.23,24 In this study, the risk of serious infections re-
mained stable throughout the study for all indications. This
Figure 2. Time to first serious infection, by indication. Shown are patients with JIA (blue line), Ps (green line), and CD (red
line). The first quartile, median, and third quartile are not estimable based on the data. JIA, juvenile idiopathic arthritis (includes
patients with pJIA and ERA); n, patients at risk; Ps, psoriasis.
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is consistent with adult populations, in which treatment with
adalimumab resulted in a generally stable risk of serious in-
fections across multiple indications.10 Furthermore, the rates
of serious infection observed with adalimumab treatment in
pediatric patients with JIA (including pJIA and ERA) and CD
were comparable with those reported in studies of adult pa-
tients with rheumatologic diseases (including rheumatoid ar-
thritis, ankylosing spondylitis, and nonradiographic axial
spondyloarthritis) and CD.25,26 Importantly, no increased risk
was observed for overall AEs or infections in patients with pJIA
who transitioned into adulthood during therapy with
adalimumab (n = 51).27
The rate of serious infection in the general pediatric popu-
lation (aged 0-14 years) has been reported to be approxi-
mately 1% per year.28,29 A systematic review of anti-TNF therapy
in pediatric inflammatory bowel disease indicated that the
serious infection rate with anti-TNF treatment was compa-
rable with that of immunomodulators but was significantly
lower than the expected rate with corticosteroid treatment in
pediatric patients.30 In this analysis, differences in SAEs, par-
ticularly infections, between patient populations may have oc-
curred in part because of differences in the use of concomitant
immunosuppressive medications; an analysis by immunosup-
pressant use was not conducted. However, patients who re-
ceived concomitant systemic corticosteroids had a greater
incidence and rate of infections and serious infections com-
pared with patients who did not.
In the absence of head-to-head trial data, it is helpful to
consider safety data for other anti-TNF agents with pediatric
indications. Etanercept is approved for the treatment of pJIA
in patients ≥2 years of age in the European Union and the
US; pediatric psoriasis in patients ≥6 and ≥4 years of age in
the European Union and the US, respectively; and ERA in
patients ≥12 years of age in the European Union.31-34 Rates of
SAEs with etanercept were reported in a registry study (n = 594,
including pJIA [90% of patients] and systemic JIA) and an
open-label extension of a randomized study (n = 58; 58%
with pJIA) of up to 8 years; rates were 7.1 and 12.3/100 PY,
respectively.31,33,35 The open-label extension reported a rate
of 4/100 PY for serious infections.35 For psoriasis, a random-
ized study of 210 pediatric patients who received etanercept
reported an exposure-adjusted SAE rate of 0.6/100 PY (ex-
cluding infections); for serious infections, the rate was 1.8/
100 PY.32 A total of 8 SAEs (including 2 patients with infectious
events) were reported during the open-label extension, of
which only 1 (cellulitis) was considered treatment-related.36
Infliximab is approved for the treatment of moderate to se-
verely active CD in pediatric patients who did not respond
to conventional therapy.37 In the 54-week REACH study (a
randomized, multicenter, open-label study to evaluate the
safety and efficacy of anti-TNF chimeric monoclonal anti-
body [infliximab, REMICADE] in pediatric subjects with
moderate-to-severe CD, N = 103), incidence rates of SAEs
and serious infections were 15% and 7%, respectively,38 whereas
incidence rates of 33% and 10% were reported in the open-
label extension study (N = 60), with most patients having <3
years of exposure.39
Registry data documenting patients treated with adalimumab
for JIA in routine clinical practice are available.11-13 The rates
of AEs and SAEs were 64.5 and 4.9 events/100 PY, respec-
tively, for patients treated with adalimumab ± concomitant
therapy (eg, nonsteroidal anti-inflammatory drugs, cortico-
steroids, methotrexate, and other disease-modifying antirheu-
matic drugs) in an interim analysis (n = 552, 679 PY of
exposure) of the Biologika in der Kinderrheumatologie Reg-
ister (BIKER) JIA registry.11 Similarly, in the 6-year interim
analysis of the STRIVE registry, a multicenter, longitudinal
postmarketing, observational study to assess long-term safety
and effectiveness of HUMIRA (adalimumab; AbbVie Inc,North
Chicago, Illinois) in children with moderately to severely active
polyarticular or polyarticular-course juvenile idiopathic ar-
thritis, patients with pJIA treated with adalimumab ± metho-
trexate (n = 543) had observed rates of AEs and SAEs of 43.7
and 7.5 events/100 PY, respectively.13
Opportunistic infections, excluding oral candidiasis and TB,
were low in our analysis, consistent with findings in adults
treated with adalimumab across multiple indications,10 and oc-
curred only in pediatric patients with CD. Opportunistic in-
fections are generally rare in pediatric patients treated with TNF
inhibitors based on previous studies.11,33,38,39 Worsening/new
onset of psoriasis was observed in 4% of all pediatric pa-
tients treated with adalimumab in our study. In an interim
analysis of multiple therapies, 6 cases of new-onset psoriasis
were observed in pediatric patients with JIA treated with
adalimumab ± concomitant therapy in the BIKER registry
(n = 552); this event was not observed in patients receiving other
therapies (etanercept [n = 2000], tocilizumab [n = 108]), or
methotrexate [n = 1517]).11 In the present analysis, the rate of
uveitis in pediatric patients treated with adalimumab was low
across indications (0.6 events/100 PY) and among patients with
JIA (0.7 events/100 PY). It should be noted that uveitis is
comorbid of JIA. In an analysis of the BIKER registry, the rate
of uveitis was 5.4 events/100 PY for patients with JIA treated
with adalimumab ± concomitant therapy.11 In the 6-year interim
analysis of the STRIVE registry of pJIA, 13% of patients
(68/543) treated with adalimumab ± methotrexate reported
uveitis (including 42 patients with uveitis present at registry
entry and 26 patients with first documentation of uveitis
postenrollment).40 Most patients in the STRIVE registry had
no new onset of uveitis or had stabilized uveitis. The benefi-
cial role of adalimumab for JIA-associated uveitis was dem-
onstrated in the randomized-controlled trial of the clinical
effectiveness, SafetY and Cost effectiveness of Adalimumab in
combination with MethOtRExate for the treatment of juve-
nile idiopathic arthritis associated uveitis (SYCAMORE);
adalimumab treatment controlled inflammation and led to a
lower rate of treatment failure vs placebo in patients with JIA-
associated uveitis taking methotrexate.41
Although this analysis provides important data on the safety
of adalimumab in pediatric populations, some limitations must
be considered. For example, there were relatively low numbers
of patients in certain age groups (eg, <4 years old), as well as
in certain disease indications (eg, ERA), limiting conclusions
for these groups. In addition, further follow-up is warranted
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to assess the impact of longer treatment exposure for certain
AEs (such as malignancies), compare safety between prepu-
bertal and pubertal children, and collect long-term immuno-
genicity data across pediatric indications. Furthermore, because
of differences between study populations (underlying dis-
eases, concomitant medications, adalimumab dose, and/or du-
ration of exposure), no direct statistical comparisons across
indications were performed; overall comparisons across indi-
cations require caution. The safety analysis also is limited by
the paucity of placebo-controlled studies, in part due to the
withdrawal design of several studies,3,4 and that non–AbbVie-
sponsored clinical trials were not included, such as the con-
trolled SYCAMORE trial.41 Finally, longer-term data were
obtained from open-label extension studies, which may select
for patients who tolerate therapy.Notably, vaccination data were
not captured uniformly among all studies of the current analy-
sis. Available data from patients with pJIA support routine im-
munization of patients receiving adalimumab despite a
perceived reluctance to do so.42 ■
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Figure 1. Safety analysis population.
Table IV. Individual AEs occurring in ≥10% of patients in any indication across adalimumab pediatric clinical trials
AEs
JIA (n = 274) Pediatric psoriasis (n = 111) Pediatric CD (n = 192) Total (n = 577)
No. (%)
Events
(events/100 PY) No. (%)
Events
(events/100 PY) No. (%)
Events
(events/100 PY) No. (%)
Events
(events/100 PY)
Exposure, PY NA 806.9 NA 121.5 NA 512.3 NA 1440.7
Injection-site pain 61 (22.3) 603 (74.7) 5 (4.5) 6 (4.9) 15 (7.8) 37 (7.2) 81 (14.0) 646 (44.8)
Upper respiratory tract infection 94 (34.3) 244 (30.2) 20 (18.0) 30 (24.7) 43 (22.4) 76 (14.8) 157 (27.2) 350 (24.3)
Headache 53 (19.3) 110 (13.6) 33 (29.7) 57 (46.9) 51 (26.6) 120 (23.4) 137 (23.7) 287 (19.9)
Nasopharyngitis 60 (21.9) 100 (12.4) 39 (35.1) 71 (58.4) 41 (21.4) 78 (15.2) 140 (24.3) 249 (17.3)
Injection-site reaction 42 (15.3) 176 (21.8) 4 (3.6) 7 (5.8) 22 (11.5) 41 (8.0) 68 (11.8) 224 (15.5)
Worsening of CD* 0 0 0 0 106 (55.2) 188 (36.7) 106 (18.4) 188 (13.0)
Nausea 34 (12.4) 55 (6.8) 16 (14.4) 19 (15.6) 32 (16.7) 68 (13.3) 82 (14.2) 142 (9.9)
Pyrexia 41 (15.0) 53 (6.6) 8 (7.2) 11 (9.1) 35 (18.2) 67 (13.1) 84 (14.6) 131 (9.1)
Pharyngitis 41 (15.0) 70 (8.7) 7 (6.3) 9 (7.4) 20 (10.4) 48 (9.4) 68 (11.8) 127 (8.8)
Viral infection 50 (18.2) 99 (12.3) 1 (0.9) 1 (0.8) 22 (11.5) 25 (4.9) 73 (12.7) 125 (8.7)
Abdominal pain 27 (9.9) 33 (4.1) 6 (5.4) 6 (4.9) 30 (15.6) 69 (13.5) 63 (10.9) 108 (7.5)
Arthralgia 30 (10.9) 56 (6.9) 6 (5.4) 7 (5.8) 27 (14.1) 43 (8.4) 63 (10.9) 106 (7.4)
Cough 34 (12.4) 46 (5.7) 13 (11.7) 15 (12.3) 28 (14.6) 43 (8.4) 75 (13.0) 104 (7.2)
Diarrhea 30 (10.9) 35 (4.3) 7 (6.3) 8 (6.6) 35 (18.2) 54 (10.5) 72 (12.5) 97 (6.7)
Vomiting 32 (11.7) 35 (4.3) 10 (9.0) 12 (9.9) 30 (15.6) 49 (9.6) 72 (12.5) 96 (6.7)
Oropharyngeal pain 26 (9.5) 28 (3.5) 9 (8.1) 11 (9.1) 34 (17.7) 56 (10.9) 69 (12.0) 95 (6.6)
Sinusitis 34 (12.4) 46 (5.7) 3 (2.7) 3 (2.5) 20 (10.4) 38 (7.4) 57 (9.9) 87 (6.0)
Rash 40 (14.6) 46 (5.7) 2 (1.8) 2 (1.6) 18 (9.4) 28 (5.5) 60 (10.4) 76 (5.3)
Worsening of JIA* 45 (16.4) 73 (9.0) 0 0 0 0 45 (7.8) 73 (5.1)
Contusion 29 (10.6) 56 (6.9) 4 (3.6) 4 (3.3) 8 (4.2) 12 (2.3) 41 (7.1) 72 (5.0)
Upper abdominal pain 14 (5.1) 17 (2.1) 8 (7.2) 14 (11.5) 22 (11.5) 36 (7.0) 44 (7.6) 67 (4.7)
Gastroenteritis 32 (11.7) 42 (5.2) 4 (3.6) 4 (3.3) 11 (5.7) 14 (2.7) 47 (8.1) 60 (4.2)
Fatigue 12 (4.4) 14 (1.7) 8 (7.2) 11 (9.1) 25 (13.0) 31 (6.1) 45 (7.8) 56 (3.9)
Constipation 12 (4.4) 13 (1.6) 1 (0.9) 1 (0.8) 22 (11.5) 34 (6.6) 35 (6.1) 48 (3.3)
*Worsening refers to worsening of the underlying disease.
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Table VI. Overview of infections and serious infections by concomitant systemic corticosteroid use
AEs, n (%)
JIA (n = 274) Pediatric psoriasis (n = 111) Pediatric CD (n = 192) Total (n = 577)
With (n = 117) Without (n = 157) With (n = 4) Without (n = 107) With (n = 104) Without (n = 88) With (n = 225) Without (n = 352)
Any infection 102 (87.2) 122 (77.7) 4 (100) 78 (72.9) 82 (78.8) 63 (71.6) 188 (83.6) 263 (74.7)
Infections in >10% of patients in the total groups
Upper respiratory tract infection 48 (41.0) 46 (29.3) 1 (25.0) 19 (17.8) 23 (22.1) 20 (22.7) 72 (32.0) 85 (24.1)
Nasopharyngitis 29 (24.8) 31 (19.7) 0 39 (36.4) 23 (22.1) 18 (20.5) 52 (23.1) 88 (25.0)
Viral infection 26 (22.2) 24 (15.3) 0 1 (0.9) 16 (15.4) 6 (6.8) 42 (18.7) 31 (8.8)
Influenza 16 (13.7) 9 (5.7) 1 (25.0) 9 (8.4) 15 (14.4) 2 (2.3) 32 (14.2) 20 (5.7)
Pharyngitis 18 (15.4) 23 (14.6) 1 (25.0) 6 (5.6) 10 (9.6) 10 (11.4) 29 (12.9) 39 (11.1)
Sinusitis 12 (10.3) 22 (14.0) 0 3 (2.8) 15 (14.4) 5 (5.7) 27 (12.0) 30 (8.5)
Gastroenteritis 18 (15.4) 14 (8.9) 1 (25.0) 3 (2.8) 7 (6.7) 4 (4.5) 26 (11.6) 21 (6.0)
Rhinitis 13 (11.1) 12 (7.6) 2 (50.0) 5 (4.7) 8 (7.7) 4 (4.5) 23 (10.2) 21 (6.0)
Urinary tract infection 14 (12.0) 7 (4.5) 0 2 (1.9) 9 (8.7) 7 (8.0) 23 (10.2) 16 (4.5)
Infections of special interest
Oral candidiasis 1 (0.9) 1 (0.6) 0 0 2 (1.9) 1 (1.1) 3 (1.3) 2 (0.6)
Herpes zoster 5 (4.3) 3 (1.9) 0 3 (2.8) 6 (5.8) 2 (2.3) 11 (4.9) 8 (2.3)
Any parasitic infection 3 (2.6) 1 (0.6) 0 0 1 (1.0) 0 4 (1.8) 1 (0.3)
TB
Active 0 1 (0.6) 0 0 0 0 0 1 (0.3)
Latent 0 1 (0.6) 1 (25.0) 1 (0.9) 1 (1.0) 0 2 (0.9) 2 (0.6)
Opportunistic infection (excluding TB and oral candidiasis) 0 0 2 (1.9) 2 (2.3) 0 0 2 (0.9) 2 (0.6)
Any serious infection 12 (10.3) 9 (5.7) 0 1 (0.9) 18 (17.3) 7 (8.0) 30 (13.3) 17 (4.8)
Serious infections in >1 patient in total group
Pneumonia 3 (2.6) 1 (0.6) 0 0 1 (1.0) 1 (1.1) 4 (1.8) 2 (0.6)
Herpes zoster 3 (2.6) 0 0 0 0 0 3 (1.3) 0
Gastroenteritis 0 0 0 0 2 (1.9) 0 2 (0.9) 0
Appendicitis 2 (1.7) 2 (1.3) 0 0 0 0 2 (0.9) 2 (0.6)
Abdominal abscess 0 0 0 0 2 (1.9) 1 (1.1) 2 (0.9) 1 (0.3)
Anal abscess 0 0 0 0 2 (1.9) 1 (1.1) 2 (0.9) 1 (0.3)
Pharyngitis 0 2 (1.3) 0 0 0 0 0 2 (0.6)
Subcutaneous abscess 0 0 0 0 1 (1.0) 1 (1.1) 1 (0.4) 1 (0.3)
Urinary tract infection 1 (0.9) 1 (0.6) 0 0 0 0 1 (0.4) 1 (0.3)
Viral infection 0 1 (0.6) 0 0 1 (1.0) 0 1 (0.4) 1 (0.3)
Concomitant corticosteroid use (at baseline and/or during the study) was permitted in all studies except for psoriasis; however, 4 patients in the psoriasis study received short courses of therapy for medical conditions other than psoriasis (bronchial obstructive
syndrome, bronchospasm, upper respiratory tract infection, and preplanned cosmetic surgery). For JIA, changes in concomitant corticosteroid use were not permitted during the blinded portions of any study, but changes were possible in open-label extension
studies; for CD, corticosteroids could be discontinued in IMAgINE I and II studies.
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Table VII. Infections and serious infections per 100 PY by concomitant systemic corticosteroid use
AEs (events/PY)
JIA (n = 274) Pediatric psoriasis (n = 111) Pediatric CD (n = 192) Total (n = 577)
With
(PY = 369.7)
Without
(PY = 437.2)
With
(PY = 5.6)
Without
(PY = 116.0)
With
(PY = 292.4)
Without
(PY = 219.9)
With
(PY = 667.6)
Without
(PY = 773.0)
Any infection 627 (169.6) 589 (134.7) 11 (196.4) 194 (167.2) 420 (143.6) 256 (116.4) 1058 (158.5) 1039 (134.4)
Infections with >5.0 events/PY in the total group
Upper respiratory tract infection 117 (31.6) 127 (29.0) 1 (17.9) 29 (25.0) 48 (16.4) 28 (12.7) 166 (24.9) 184 (23.8)
Nasopharyngitis 53 (14.3) 47 (10.8) 0 71 (61.2) 45 (15.4) 33 (15.0) 98 (14.7) 151 (19.5)
Viral infection 56 (15.1) 43 (9.8) 0 1 (0.9) 16 (5.5) 9 (4.1) 72 (10.8) 53 (6.9)
Influenza 16 (4.3) 12 (2.7) 1 (17.9) 10 (8.6) 23 (7.9) 2 (0.9) 40 (6.0) 24 (3.1)
Pharyngitis 27 (7.3) 43 (9.8) 1 (17.9) 8 (6.9) 19 (6.5) 29 (13.2) 47 (7.0) 80 (10.3)
Sinusitis 19 (5.1) 27 (6.2) 0 3 (2.6) 31 (10.6) 7 (3.2) 50 (7.5) 37 (4.8)
Gastroenteritis 24 (6.5) 18 (4.1) 1 (17.9) 3 (2.6) 10 (3.4) 4 (1.8) 35 (5.2) 25 (3.2)
Rhinitis 19 (5.1) 18 (4.1) 2 (35.7) 5 (4.3) 18 (6.2) 4 (1.8) 39 (5.8) 27 (3.5)
Urinary tract infection 21 (5.7) 10 (2.3) 0 2 (1.7) 13 (4.4) 8 (3.6) 34 (5.1) 20 (2.6)
Infections of special interest
Oral candidiasis 1 (0.3) 1 (0.2) 0 0 5 (1.7) 1 (0.5) 6 (0.9) 2 (0.3)
Herpes zoster 6 (1.6) 3 (0.7) 0 3 (2.6) 7 (2.4) 2 (0.9) 13 (1.9) 8 (1.0)
Any parasitic infection 4 (1.1) 1 (0.2) 0 0 1 (0.3) 0 5 (0.7) 1 (0.1)
TB
Active 0 1 (0.2) 0 0 0 0 0 1 (0.1)
Latent 0 1 (0.2) 1 (17.9) 1 (0.9) 1 (0.3) 0 2 (0.3) 2 (0.3)
Opportunistic infection (excluding TB and oral candidiasis) 0 0 0 0 2 (0.7) 2 (0.9) 2 (0.3) 2 (0.3)
Any serious infection 13 (3.5) 9 (2.1) 0 1 (0.9) 24 (8.2) 10 (4.5) 37 (5.5) 20 (2.6)
Serious infections with >1 event in total group
Pneumonia 3 (0.8) 1 (0.2) 0 0 2 (0.7) 2 (0.9) 5 (0.7) 3 (0.4)
Herpes zoster 3 (0.8) 0 0 0 0 0 3 (0.4) 0
Gastroenteritis 0 0 0 0 2 (0.7) 0 2 (0.3) 0
Appendicitis 2 (0.5) 2 (0.5) 0 0 0 0 2 (0.3) 2 (0.3)
Abdominal abscess 0 0 0 0 2 (0.7) 2 (0.9) 2 (0.3) 2 (0.3)
Anal abscess 0 0 0 0 2 (0.7) 1 (0.5) 2 (0.3) 1 (0.1)
Pharyngitis 0 2 (0.5) 0 0 0 0 0 2 (0.3)
Subcutaneous abscess 0 0 0 0 1 (0.3) 1 (0.5) 1 (0.1) 1 (0.1)
Urinary tract infection 1 (0.3) 1 (0.2) 0 0 0 0 1 (0.1) 1 (0.1)
Viral infection 0 1 (0.2) 0 0 1 (0.3) 0 1 (0.1) 1 (0.1)
Concomitant corticosteroid use (at baseline and/or during the study) was permitted in all studies except for psoriasis; however, 4 patients in the psoriasis study received short courses of therapy for medical conditions other than psoriasis (bronchial obstructive
syndrome, bronchospasm, upper respiratory tract infection, and preplanned cosmetic surgery). For JIA, changes in concomitant corticosteroid use were not permitted during the blinded portions of any study, but changes were possible in open-label extension
studies; for CD, corticosteroids could be discontinued in IMAgINE I and II studies.
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